Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2022-07-21 00:00:00 ET · period of report 2022-07-19 · accession 0001567619-22-014301 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-07-21 | 2022-07-19 | CTMX | Peterson Amy C. | EVP, Chief Development Off | A - Grant | $0.00 | +20.0K | 70.2K | +40% | $0 | |
| 2022-07-21 | 2022-07-20 | CTMX | Peterson Amy C. | EVP, Chief Development Off | S - Sale | $1.42 | -7,463 | 62.7K | -11% | -$10.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-19 | A | A | 20,000 | $0.00 | 70,153 | D | — | — | (F3) Reflects the adjusted total which includes the purchase of 3,732 shares under the Cytomx Therapeutics Employee Stock Purchase Plan on May 31, 2022. (F2) Includes 40,000 restricted stock units. |
| 2 | Common | Common Stock | 2022-07-20 | S | D | 7,463 | $1.42 | 62,690 | D | — | — | (F2) Includes 40,000 restricted stock units. |